CGON CG Oncology, Inc.
FY2025 10-K
CG Oncology, Inc. (CGON) filed its fiscal year 2025 10-K annual report with the SEC on Feb 27, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Late-stage clinical biopharma developing cretostimogene, an oncolytic immunotherapy targeting non-muscle invasive bladder cancer (NMIBC)
- • New emphasis: BLA submission initiated Q4 2025 for high-risk BCG-unresponsive NMIBC; expanded Phase 2/3 trials including combination with gemcitabine and pembrolizumab
Management Discussion & Analysis
- • Revenue $4.0M in 2025 vs $1.1M in 2024; $3.2M commercial/development revenue in 2025 (vs $0 in 2024)
- • Net loss $161.0M in 2025 vs $88.0M in 2024; operating costs $194.8M (2025) vs $115.8M (2024) with general & admin $73.5M vs $33.7M
Risk Factors
- • Regulatory risk from FDA on novel gene-modified virus cretostimogene may delay BLA approval; FDA may issue Complete Response Letter requiring more trials
- • Macroeconomic risk from global clinical trial delays due to geopolitical issues in foreign countries impacting patient enrollment and regulatory approvals
Financial SummaryXBRL
Revenue
$4M
Net Income
-$161M
Operating Margin
-4722.1%
Net Margin
-3985.0%
ROE
-21.4%
Total Assets
$792M
EPS (Diluted)
$-2.08
Operating Cash Flow
-$132M
Source: XBRL data from CG Oncology, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CG Oncology, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.